Kineticos launches Kinvard Bio to advance next-generation antibiotics in the fight against AMR

Kineticos Life Sciences has launched Kinvard Bio, Inc., an anti-infectives biotech company based on groundbreaking research from Harvard’s Myers Lab. The company is funded by the Kineticos AMR Accelerator Fund I (KAMRA I), which aims to combat antimicrobial resistance (AMR). The research team, led by Professor Andy Myers, developed a class of lincosamide antibiotics called Oxepanoprolinamides (OPPs) that could overcome drug-resistant infections. The technology was licensed by Harvard’s Office of Technology Development to facilitate the progress of the research towards clinical application. Kinvard Bio is focusing on developing oral and IV formulations for challenging acute and chronic drug-resistant infections, such as bacterial pneumonia, complicated urinary tract infections, and nontuberculosis mycobacteria lung disease.